Neurocrine BiosciencesNBIX

NASDAQ · USA · Segment 3 of 8 in the Medicine, pharma & life science value chain: Biotech & innovation

Ingrezza for tardive dyskinesia, plus a wider neurology and endocrine portfolio.

Biotech & innovation: Innovation-driven biotech companies focused on novel treatment modalities.

Key metrics

Market cap

$15.5B

Price

$153.04

Today

+0.3%

Return YTD

+7.6%

Return 1Y

+12.8%

P/E

22.0

P/S

4.6

P/B

4.2

Data as of 2026-08-25 · updates daily after U.S. close

Theme exposure

Neuro biotechNeurologyEndocrinologyCNS therapy

In the value chain

Products & services

Ingrezza (tardive dyskinesia)
Endocrine portfolio
CNS pipeline

Competitors

Teva
AbbVie
Sage Therapeutics

Risks

Ingrezza concentration
Clinical pipeline risk

Supply chain

Supplies →

McKessonMCK

← Suppliers

IQVIA HoldingsIQV

Full supply chain for NBIX →

Same segment: Biotech & innovation

AmgenAMGN Gilead SciencesGILD Vertex PharmaceuticalsVRTX RegeneronREGN BiogenBIIB Alnylam PharmaceuticalsALNY ModernaMRNA IncyteINCY

Compare NBIX

NBIX vs AMGN NBIX vs GILD NBIX vs VRTX NBIX vs REGN NBIX vs BIIB NBIX vs ALNY

See where Neurocrine Biosciences sits in the full Medicine, pharma & life science map: every segment from upstream suppliers to end markets, with daily metrics.Open the Life science value chain →